News

Net profit of OneSource Specialty Pharma reported to Rs 25.00 crore in the quarter ended June 2026 as against net loss of Rs 0.19 crore during the previous quarter ended June 2025. Sales rose 37.20% to Rs 449.02 crore in the quarter ended June 2026 as against Rs 327.27 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales449.02327.27 37 OPM %27.4727.04 - PBDT96.3466.27 45 PBT24.59-1.53 LP NP25.00-0.19 LP Powered by Capital Market - Live News

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 24 July 2026.

OneSource Specialty Pharma and Formycon AG, an independent biosimilar developer headquartered in Munich, today announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics` facility in Bangalore. The collaboration brings together Formycon�s Biosimilar development excellence with OneSource`s end-to-end biologics manufacturing expertise to support Formycon`s biosimilar programs for global markets.

OneSource Specialty Pharma announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility (SPD) of OneSource Specialty Pharma located at Opp. IIM, Bilekahalli, Bannerghatta Road, Bengaluru, 560076 from 22 June 2026 to 30 June 2026. The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame.

Net profit of OneSource Specialty Pharma declined 95.33% to Rs 4.60 crore in the quarter ended March 2026 as against Rs 98.50 crore during the previous quarter ended March 2025. Sales rose 0.53% to Rs 428.22 crore in the quarter ended March 2026 as against Rs 425.95 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 73.80 crore in the year ended March 2026 as against net loss of Rs 17.97 crore during the previous year ended March 2025. Sales declined 1.61% to Rs 1421.59 crore in the year ended March 2026 as against Rs 1444.85 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales428.22425.95 1 1421.591444.85 -2 OPM %21.4742.85 -21.4032.29 - PBDT71.50151.99 -53 197.06317.67 -38 PBT-0.3283.50 PL -82.0343.78 PL NP4.6098.50 -95 -73.80-17.97 -311 Powered by Capital Market - Live News